6541 fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Tanvex BioPharma, Inc. operates as clinical stage company, which engages in the research and development, production, and sale of pharmaceutical products. It products include filgrastim, trastuzumab, pegfilgrastim, bevacizumab, and pertuzumab injections. The company was founded by Yu Tien Chao on May 8, 2013 and is headquartered in Taipei, Taiwan.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
6541 has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company